The Q2 2026 revenue of $28.5 million marks a critical commercial inflection, but the 97.2% gross margin is almost entirely consumed by $13.8 million in R&D expenses, resulting in a near-breakeven operating margin of 0.3%.
Omeros Corporation (OMER) annual income statement — 19-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 |
|---|
| Sales/Revenue | 74.36M | 0 | 0 | 0 | 0 | 0 | 0 | 111.81M | 29.87M | 64.83M | 41.62M | 13.51M | 539K | 1.6M | 6.02M | 4.52M | 2.1M | 1.44M | 1.17M | 1.92M |
| Revenue Growth % | - | - | - | - | - | - | -100% | 274.33% | -53.93% | 55.77% | 208.07% | 2406.31% | -66.31% | -73.43% | 33.11% | 114.92% | 45.78% | 23.42% | -39.16% | - |
| Cost of Goods Sold | 33.06M | 0 | 0 | 0 | 0 | 1.39M | 1.62M | 2.65M | 512K | 1.08M | 1.41M | 1.04M | 26.73M | 18.33M | 18.46K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | 2.37% | 1.71% | 1.66% | 3.39% | 7.71% | 4958.81% | 1145.38% | 0.31% | - | - | - | - | - |
| Gross Profit | 41.3M | 0 | 0 | 0 | 0 | -1.39M | -1.62M | 109.15M | 29.36M | 63.75M | 40.2M | 12.47M | -26.19M | -16.73M | 6M | 4.52M | 2.1M | 1.44M | 1.17M | 1.92M |
| Gross Margin % | 55.54% | - | - | - | - | - | - | 97.63% | 98.29% | 98.34% | 96.61% | 92.29% | -4858.81% | -1045.38% | 99.69% | 100% | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | - | - | - | - | 100% | 14.23% | -101.48% | 271.81% | -53.95% | 58.56% | 222.47% | 147.61% | -56.58% | -378.6% | 32.7% | 114.92% | 45.78% | 23.42% | -39.16% | - |
| Operating Expenses | 113.83M | 122.8M | 169.26M | 164.53M | 163.39M | 172.23M | 155.3M | 172.53M | 141.58M | 107.64M | 94.48M | 83.71M | 70.55M | 52.12M | 42.91M | 31.93M | 32.21M | 22.2M | 25.7M | 26.32M |
| OpEx % of Revenue | - | - | - | - | - | - | - | 154.32% | 474.01% | 166.05% | 227.02% | 619.63% | 13088.5% | 3257.25% | 712.5% | 705.88% | 1530.21% | 1537.53% | 2196.15% | 1368.69% |
| Selling, General & Admin | 51.41M | 41.5M | 49.73M | 49.66M | 50.67M | 53.46M | 47.69M | 62.84M | 51.72M | 52.04M | 43.78M | 35.33M | 22.6M | 15.82M | 10.98M | 8.22M | 8.75M | 5.27M | 7.84M | 10.4M |
| SG&A % of Revenue | - | - | - | - | - | - | - | 56.2% | 173.16% | 80.28% | 105.2% | 261.51% | 4193.14% | 988.69% | 182.41% | 181.61% | 415.49% | 365.17% | 670.51% | 540.72% |
| Research & Development | 62.42M | 81.3M | 119.52M | 114.87M | 112.72M | 118.78M | 107.61M | 109.7M | 89.86M | 55.6M | 50.7M | 48.38M | 47.95M | 36.3M | 31.92M | 23.72M | 23.46M | 16.93M | 17.85M | 15.92M |
| R&D % of Revenue | - | - | - | - | - | - | - | 98.11% | 300.86% | 85.77% | 121.82% | 358.12% | 8895.36% | 2268.56% | 530.09% | 524.27% | 1114.73% | 1172.37% | 1525.64% | 827.98% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 945K | 0 | -207K | 574K | 130K | 0 | 0 | 0 | 0 | -125K |
| Operating Income | -41.93M | -122.8M | -169.26M | -164.53M | -163.39M | -173.62M | -156.92M | -63.38M | -112.22M | -43.9M | -54.28M | -71.24M | -70.01M | -50.52M | -36.88M | -27.41M | -30.11M | -20.76M | -24.52M | -24.4M |
| Operating Margin % | -56.39% | - | - | - | - | - | - | -56.69% | -375.73% | -67.71% | -130.42% | -527.34% | -12988.5% | -3157.25% | -612.5% | -605.88% | -1430.21% | -1437.53% | -2096.15% | -1268.69% |
| Operating Income Growth % | - | 27.45% | -2.87% | -0.7% | 5.89% | -10.64% | -147.57% | 43.52% | -155.66% | 19.13% | 23.81% | -1.76% | -38.59% | -36.96% | -34.57% | 8.96% | -45.03% | 15.36% | -0.52% | - |
| EBITDA | -41.1M | -121.83M | -168.31M | -163.61M | -162.44M | -172.23M | -155.3M | -61.59M | -111.26M | -43.34M | -53.98M | -71.03M | -69.68M | -50.21M | -36.56M | -26.98M | -29.63M | -20.31M | -24.09M | -24.02M |
| EBITDA Margin % | -55.28% | - | - | - | - | - | - | -55.09% | -372.51% | -66.86% | -129.7% | -525.79% | -12928.01% | -3138.38% | -607.19% | -596.26% | -1407.79% | -1406.3% | -2059.06% | -1249.19% |
| EBITDA Growth % | 67.98% | 27.61% | -2.87% | -0.72% | 5.69% | -10.9% | -152.15% | 44.64% | -156.69% | 19.7% | 24.01% | -1.93% | -38.77% | -37.33% | -35.55% | 8.97% | -45.93% | 15.71% | -0.29% | - |
| D&A (Non-Cash Add-back) | 826K | 964K | 950K | 920K | 952K | 1.39M | 1.62M | 1.79M | 962K | 551K | 300K | 209K | 326K | 302K | 320K | 435K | 472K | 451K | 434K | 375K |
| EBIT | 95.8M | -2.8M | -157.95M | -144.08M | -159.33M | -171.88M | -169.64M | -61.83M | -123.43M | -42.45M | -58.93M | -71.52M | -70.2M | -37.43M | -36.72M | -26.66M | -27.72M | -20.76M | -24.52M | -22.94M |
| Net Interest Income | -25.09M | 5.06M | -13.37M | -14.5M | -18.64M | -19.65M | -26.1M | -22.66M | -16.25M | -11.03M | -7.82M | -3.57M | -3.47M | -2.37M | -1.73M | -1.88M | -1.53M | -2.2M | -335K | -151K |
| Interest Income | 3.34M | 5.06M | 11.3M | 16.34M | 4.06M | 17.93K | 654K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 28.43M | 0 | 24.68M | 30.84M | 22.7M | 19.67M | 26.75M | 22.66M | 16.25M | 11.03M | 7.82M | 3.57M | 3.47M | 2.37M | 1.73M | 1.88M | 1.53M | 2.2M | 335K | 151K |
| Other Income/Expense | 118.02M | 120M | -13.37M | -10.39M | -18.64M | -17.93M | -39.47M | -21.1M | -27.46M | -9.59M | -12.47M | -3.86M | -3.67M | 10.72M | -1.56M | -1.14M | 855K | -331K | 698K | 1.31M |
| Pretax Income | 76.09M | -2.8M | -182.63M | -174.92M | -182.03M | -191.55M | -196.39M | -84.49M | -139.69M | -53.48M | -66.75M | -75.1M | -73.67M | -39.8M | -38.44M | -26.66M | -27.72M | -18.89M | -23.83M | -23.09M |
| Pretax Margin % | 102.34% | - | - | - | - | - | - | -75.57% | -467.68% | -82.5% | -160.38% | -555.9% | -13668.46% | -2487.25% | -638.39% | -589.35% | -1316.67% | -1307.96% | -2036.5% | -1200.78% |
| Income Tax | 2.14M | 2.01M | 0 | 0 | 0 | 0 | -23.26M | 0 | -12.93M | 0 | 0 | 0 | 0 | 0 | 0 | 1.14M | -855K | 331K | 0 | 26K |
| Effective Tax Rate % | 2.82% | -71.96% | 0% | 0% | 0% | 0% | 11.84% | 0% | 9.26% | 0% | 0% | 0% | 0% | 0% | 0% | -4.26% | 3.08% | -1.75% | 0% | -0.11% |
| Net Income | 98.39M | -3.35M | -156.81M | -117.81M | 47.42M | -111.41M | -138.06M | -84.49M | -126.76M | -53.48M | -66.75M | -75.1M | -73.67M | -39.8M | -38.44M | -28.55M | -29.25M | -21.09M | -23.83M | -23.09M |
| Net Margin % | 132.32% | - | - | - | - | - | - | -75.57% | -424.39% | -82.5% | -160.38% | -555.9% | -13668.46% | -2487.25% | -638.39% | -630.99% | -1389.6% | -1460.46% | -2036.5% | -1200.78% |
| Net Income Growth % | 181.2% | 97.86% | -33.11% | -348.46% | 142.56% | 19.3% | -63.41% | 33.35% | -137.01% | 19.87% | 11.12% | -1.93% | -85.13% | -3.52% | -34.67% | 2.41% | -38.7% | 11.49% | -3.19% | - |
| Net Income (Continuing) | 73.95M | -4.81M | -182.63M | -174.92M | -182.03M | -191.55M | -173.13M | -84.49M | -126.76M | -53.48M | -66.75M | -75.1M | -73.67M | -39.8M | -38.44M | -28.55M | -29.25M | -21.09M | -23.83M | -23.09M |
| Discontinued Operations | 4M | 1.46M | 25.81M | 57.11M | 229.45M | 80.13M | 35.07M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 1.35 | -0.05 | -2.70 | -1.88 | 0.46 | -1.79 | -2.41 | -2.16 | -2.61 | -1.17 | -1.65 | -2.00 | -2.22 | -1.39 | -1.59 | -1.29 | -1.37 | -2.92 | -2.22 | -1.62 |
| EPS Growth % | 169.31% | 98.05% | -43.62% | -508.7% | 125.7% | 25.73% | -11.57% | 17.24% | -123.08% | 29.09% | 17.5% | 9.91% | -59.71% | 12.58% | -23.26% | 5.84% | 53.08% | -31.53% | -37.04% | - |
| EPS (Basic) | - | -0.05 | -2.70 | -1.88 | 0.46 | -1.79 | -2.41 | -2.16 | -2.61 | -1.17 | -1.65 | -2.00 | -2.22 | -1.39 | -1.59 | -1.29 | -1.37 | -2.92 | -2.22 | -1.62 |
| Diluted Shares Outstanding | 72.98M | 63.51M | 58.17M | 62.74M | 62.74M | 62.34M | 57.18M | 49.52M | 48.58M | 45.54M | 40.45M | 37.56M | 33.23M | 28.56M | 24.16M | 22.21M | 21.42M | 7.22M | 10.75M | 14.27M |
| Basic Shares Outstanding | 72.98M | 63.51M | 58.17M | 62.74M | 62.74M | 62.34M | 57.18M | 49.52M | 48.58M | 45.54M | 40.45M | 37.56M | 33.23M | 28.56M | 24.16M | 22.21M | 21.42M | 7.22M | 10.75M | 14.27M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying OMER stock.
For fiscal year 2025, Omeros Corporation (OMER) reported total revenue of $0.0M. This represents a 100.0% decline compared to $1.9M in 2007.
Omeros Corporation (OMER) reported a net loss of $3.4M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Critical liquidity and regulatory risk
Metrics are mathematically derived from official filings.
Revenue Emergence from Royalty Base
Omeros's revenue trajectory has shifted from zero to a meaningful $28.5 million in Q2 2026, driven by the initial commercial launch of YARTEMLEA, marking a critical transition from a pure R&D entity to a commercial-stage biotech.
The sudden appearance of $28.5 million in revenue in Q2 2026, after multiple quarters of zero reported revenue, represents a fundamental inflection in the company's income statement. This revenue is likely tied to the commercial launch of YARTEMLEA, suggesting the company is now generating sales from a marketed product rather than relying solely on milestone payments or royalties. The durability of this revenue stream is the key question, as the company's prior revenue history was inconsistent and often zero.
Royalty-Like Gross Margins Mask Operating Losses
The reported 97.2% gross margin in Q2 2026 is exceptionally high, suggesting a royalty or high-margin specialty product structure, but this is completely offset by heavy R&D and SG&A spending, resulting in a near-breakeven operating margin.
The 97.2% gross margin is characteristic of a royalty stream or a product with minimal cost of goods sold, which aligns with the company's transition to a royalty-based model for Omidria. However, this structural advantage is negated by the company's high fixed-cost base, with R&D and SG&A totaling $27.7 million in Q2 2026, nearly matching the gross profit. This indicates that while the product itself is highly profitable, the corporate overhead required to support it and advance the pipeline remains substantial.
Operating Leverage Unproven at Scale
Despite achieving a positive operating income of $74,000 in Q2 2026, the company's operating leverage remains unproven, as the result appears driven by a single quarter's revenue spike rather than a sustainable reduction in the cost base.
The shift from a $17.4 million operating loss in Q1 2026 to a marginal profit in Q2 2026 is a positive signal, but it is almost entirely attributable to the $18.6 million sequential increase in revenue. The combined R&D and SG&A expenses actually increased slightly quarter-over-quarter, suggesting no meaningful improvement in overhead efficiency. True operating leverage would require demonstrating that incremental revenue can flow to the bottom line without a proportional increase in the cost structure, which has not yet been established.
R&D Dominates Cost Structure
Research and development expenses of $13.8 million in Q2 2026 represent the single largest cost line, consuming nearly half of gross profit and underscoring the company's continued heavy investment in its clinical pipeline despite recent commercial progress.
The cost structure is dominated by R&D, which at $13.8 million in Q2 2026 is roughly equal to SG&A at $13.9 million. This balance suggests the company is simultaneously funding late-stage clinical programs and building commercial capabilities. The high R&D spend is a strategic necessity for a biotech with multiple pipeline candidates, but it also means that profitability is highly sensitive to the pace of clinical trial execution and regulatory milestones.
Q2 2026: First Commercial Revenue Quarter
The second quarter of 2026 represents the most significant operational inflection in Omeros's recent history, as it marks the first quarter with substantial recognized revenue, fundamentally altering the company's income statement profile from a pure cash-burn entity.
Prior to Q2 2026, the company's income statement was characterized by zero or minimal revenue and consistent operating losses funded by cash reserves and financing. The $28.5 million in revenue in Q2 2026 changes the narrative, providing a proof-of-concept for commercial execution. This inflection point is critical because it demonstrates the company's ability to generate top-line sales, which is a prerequisite for any path to long-term profitability, though the sustainability of this initial launch quarter remains to be seen.
Sustainability of Launch Quarter in Question
The strong Q2 2026 results may represent an unsustainable launch spike, as the company's history of zero revenue quarters and a cash position of only $9.66 million suggests limited runway to support operations if the revenue ramp disappoints.
A skeptical view would focus on the fact that $28.5 million in revenue appeared suddenly after many quarters of zero, raising questions about the durability of this sales trajectory. The company's reported cash and equivalents of approximately $9.66 million is critically low, indicating that any shortfall in the expected revenue ramp could force an immediate and dilutive capital raise. Furthermore, the operating income of $74,000 is razor-thin and would quickly turn negative if R&D or SG&A spending increases or if revenue does not grow sequentially.